12:11 PM EDT, 04/04/2024 (MT Newswires) -- AngioDynamics ( ANGO ) shares rose about 10% in recent Thursday trading after the company reported its fiscal Q3 results and secured a clearance from the US Food and Drug Administration for its AlphaVac F18 System.

Earlier, the firm reported a wider fiscal Q3 adjusted loss of $0.16 per diluted share, compared with $0.03 loss a year earlier. Analysts polled by Capital IQ expected a loss of $0.14.

Net sales for the quarter ended Feb. 28 was $66 million, compared with $61 million a year earlier. Analysts in a Capital IQ survey expected $75.7 million.

The company said it now expects fiscal 2024 net sales of $270 million to $275 million to reflect the divestiture of its PICC and Midline businesses and discontinuance of its RadioFrequency ablation and Syntrax businesses. It now expects adjusted loss per share of $0.54 to $0.58 for the year.

Separately, AngioDynamics ( ANGO ) said it has received 510(k) clearance from the FDA for the AlphaVac F18 System for the treatment of pulmonary embolism, enhancing its utility in critical medical scenarios.

The clearance also broadens the applicability of the device in non-surgical removal of thrombi or emboli from the venous vasculature, the company said.

Price: 6.72, Change: +0.64, Percent Change: +10.52